Clinical Data Lilly’s Verve gambit pays off as base editor cuts cholesterol in early study BioSpaceA single 1-mg/kg dose of Eli Lilly's base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia.CardiovascularRead full story pharminent May 26, 2026 (Last updated: May 26, 2026) BioSpace A single 1-mg/kg dose of Eli Lilly’s base editor can lower LDL cholesterol levels by 62% in patients with a heritable form of hypercholesterolemia. Cardiovascular Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: All eyes on Revolution, bispecific antibodies and more at ASCO26Next: Eli Lilly to buy trio of vaccine developers in $3.8bn outlay Related Stories Clinical Data Parkinson’s drug from Biogen, Denali comes up short pharminent May 22, 2026 Clinical Data Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival pharminent May 22, 2026 Clinical Data Lilly’s triple agonist shows bariatric surgery-like weight loss results pharminent May 21, 2026
